Patents by Inventor Elisabeth I. HEATH

Elisabeth I. HEATH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENTS AND DIAGNOSTICS FOR CANCERS
    Publication number: 20200281946
    Abstract: Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin ?2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
    Type: Application
    Filed: May 5, 2020
    Publication date: September 10, 2020
    Applicant: Wayne State University
    Inventors: Qingping Dou, Huanjie Yang, Elisabeth I. Heath
  • Treatments and diagnostics for cancers
    Patent number: 10682362
    Abstract: Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin ?2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 16, 2020
    Assignee: Wayne State University
    Inventors: Qingping Dou, Huanjie Yang, Elisabeth I. Heath
  • TREATMENTS AND DIAGNOSTICS FOR CANCERS
    Publication number: 20180280412
    Abstract: Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin ?2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
    Type: Application
    Filed: October 14, 2016
    Publication date: October 4, 2018
    Inventors: Qingping Dou, Huanjie Yang, Elisabeth I. Heath
  • GALECTIN-3 AS A MARKER FOR PROSTATE CANCER
    Publication number: 20150377889
    Abstract: Provided are methods and kits for the use of galectin-3, alone or in combination with prostate specific antigen (PSA), as a marker for the presence or absence of and/or activity of prostate cancer.
    Type: Application
    Filed: February 14, 2014
    Publication date: December 31, 2015
    Applicant: Wayne State University
    Inventors: Avraham RAZ, Elisabeth I. HEATH, Balan VITALY, Lance K. HEILBRUN